Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2019
This article has no abstract
Epistemonikos ID: fb98f1812432f31746124f9fdc0dd76d1bd25cee
First added on: Feb 11, 2025